Login to Your Account



Clinic Roundup


Thursday, September 6, 2012
• Epizyme Inc., of Cambridge, Mass., said it initiated a Phase I study of EPZ-5676, a small-molecule inhibitor of histone methyltransferase DOT1L, to evaluate the drug's safety, pharmacokinetics and pharmacodynamics in escalating doses.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription